Lv15
50 积分 2023-07-26 加入
Myelofibrosis: Current unmet needs, emerging treatments, and future perspectives
2天前
已完结
Opportunities and challenges of bi-specific antibodies
3天前
已完结
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis
8天前
已完结
Analysis of 60 patients with relapsed or refractory T‐cell acute lymphoblastic leukemia and T‐cell lymphoblastic lymphoma treated with CD7‐targeted chimeric antigen receptor‐T cell therapy
9天前
已完结
Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial
9天前
已完结
Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial
10天前
已完结
Publisher Correction: Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial
10天前
已完结
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas
10天前
已完结
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas
10天前
已关闭
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas
10天前
已关闭
皖公网安备34019202002308
